Dietary modifications for enhanced cancer therapy

N Kanarek, B Petrova, DM Sabatini - Nature, 2020‏ - nature.com
Tumours depend on nutrients supplied by the host for their growth and survival.
Modifications to the host's diet can change nutrient availability in the tumour …

From Krebs to clinic: glutamine metabolism to cancer therapy

BJ Altman, ZE Stine, CV Dang - Nature Reviews Cancer, 2016‏ - nature.com
The resurgence of research into cancer metabolism has recently broadened interests
beyond glucose and the Warburg effect to other nutrients, including glutamine. Because …

[HTML][HTML] Targeting molecular mechanisms underlying treatment efficacy and resistance in osteosarcoma: a review of current and future strategies

I Lilienthal, N Herold - International journal of molecular sciences, 2020‏ - mdpi.com
Osteosarcoma is the most common primary malignant bone tumour in children and
adolescents. Due to micrometastatic spread, radical surgery alone rarely results in cure …

[HTML][HTML] Antineoplastic activity of biogenic silver and gold nanoparticles to combat leukemia: beginning a new era in cancer theragnostic

E Mostafavi, A Zarepour, H Barabadi, A Zarrabi… - Biotechnology …, 2022‏ - Elsevier
Abstract The American Cancer Society estimated around 61,090 new cases of leukemia
were diagnosed, and around 23,660 people died from this disease in the United States …

Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre …

G Bisogno, GL De Salvo, C Bergeron… - The lancet …, 2019‏ - thelancet.com
Background For more than three decades, standard treatment for rhabdomyosarcoma in
Europe has included 6 months of chemotherapy. The European paediatric Soft tissue …

Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome–positive acute lymphoblastic leukemia: A randomized clinical trial

S Shen, X Chen, J Cai, J Yu, J Gao, S Hu, X Zhai… - JAMA …, 2020‏ - jamanetwork.com
Importance A randomized clinical trial is needed to determine whether the second-
generation Abl–tyrosine kinase inhibitor dasatinib is more effective than the first-generation …

Pediatric acute lymphoblastic leukemia, version 2.2020, NCCN clinical practice guidelines in oncology

P Brown, H Inaba, C Annesley, J Beck… - Journal of the National …, 2020‏ - jnccn.org
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy.
Advancements in technology that enhance our understanding of the biology of the disease …

Cancer cell metabolism: one hallmark, many faces

JR Cantor, DM Sabatini - Cancer discovery, 2012‏ - aacrjournals.org
Cancer cells must rewire cellular metabolism to satisfy the demands of growth and
proliferation. Although many of the metabolic alterations are largely similar to those in …

Inhibition of glycolysis and glutaminolysis: an emerging drug discovery approach to combat cancer

NS Akins, TC Nielson, HV Le - Current topics in medicinal …, 2018‏ - benthamdirect.com
Cancer cells have a very different metabolism from that of normal cells from which they are
derived. Their metabolism is elevated, which allows them to sustain higher proliferative rate …

L-asparaginase in the treatment of patients with acute lymphoblastic leukemia

RA Egler, SP Ahuja, Y Matloub - Journal of Pharmacology …, 2016‏ - journals.sagepub.com
Acute lymphoblastic leukemia (ALL) is a hematologic malignancy that predominantly occurs
in children between 2 and 10 years of age. L-asparaginase is an integral component of …